Thomas Doty, MD
Endocrinology, Diabetes & Metabolism · Knoxville, TNNPI 1730184540
Payments from drug & device makers
Across 866 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$7K
- Novo Nordisk$2K
- Amgen$1K
- Lilly USA, LLC$1K
- Corcept Therapeutics$911
- Xeris Pharmaceuticals, Inc.$764
- plus $8K from 48 others
Across 3 payments — averaging $37.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$38
- Novo Nordisk$38
- GSK$38
What the payments were for
- Speaking & faculty fees$6,75032%
- Food & beverage$14,12367%
- Education$870%
- Gifts$770%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$5,450
- t-slim insulin pump$1,300
- Korlym$217
- InPen$126
- FreeStyle Libre Pro$125
- Minimed 670G System$114
- AFREZZA$113
- MINIMED 780G$111
- Repatha$102
How this compares
$21,038 in reported general payments places this provider in the 70th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 135 | $198,046 |
| MounjaroTirzepatide | 121 | $153,102 |
| JardianceEmpagliflozin | 105 | $98,767 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $51,945 |
| Tresiba Flextouch U-100Insulin Degludec | 82 | $51,103 |
| FarxigaDapagliflozin Propanediol | 31 | $38,495 |
| Repatha SureclickEvolocumab | 48 | $37,803 |
| TrulicityDulaglutide | 27 | $29,165 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 38 | $27,519 |
| Novolog FlexpenInsulin Aspart | 79 | $26,538 |
| VascepaIcosapent Ethyl | 43 | $23,544 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $14,988 |
| Victoza 3-PakLiraglutide | 11 | $14,677 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $14,481 |
| NovologInsulin Aspart | 50 | $13,586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,906 | $211,632185 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,061 | $182,268148 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $127 | $107,603118 claims |
| AstraZenecaFarxiga | $396 | $38,49531 claims |
| AbbVieSynthroid | $84 | $9,160129 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $75 | $6,456809 claims |
| PfizerLevoxyl | $104 | $1,17519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Knoxville
- Amit VoraKnoxville$579K
- David IrizarryKnoxville$96K
- Casey PageKnoxville$82K
- Mubashir MahmoodKnoxville$26K
- Daniel McCammonKnoxville$9K
- Stephen SharpNashville$25.9M
- Lisa UsdanMemphis$14.3M
- Kathryn DahirNashville$11M
- David HuffmanChattanooga$2.4M
- Pedro VelasquezMemphis$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.